Clinical Trial Update: A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

View source ↗

Summary

A real-world patient registry study to describe experiences and clinical outcomes of chronic myeloid leukemia patients in the chronic phase who are receiving ap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia - Chronic Phase | Status: NOT_YET_RECRUITING